Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Obesity01:24

Obesity

1.5K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

342
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
342
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

262
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
262
Metabolic States of the Body: Fasting and Starvation01:24

Metabolic States of the Body: Fasting and Starvation

3.2K
During the initial hours of fasting, the body uses up its glycogen stores as an energy source. Once these glycogen reserves are depleted, the body begins breaking down stored triglycerides and structural proteins. During this stage, glycerol becomes a key substrate for gluconeogenesis, while free fatty acids undergo beta-oxidation to provide energy for tissues, such as skeletal muscle. In the fasting state, the body spares protein breakdown as much as possible to conserve muscle and structural...
3.2K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

325
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
325
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

4.5K
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The weight-adjusted waist index predicts sarcopenia in community-dwelling older adults in a nationwide multicenter prospective study.

Scientific reports·2026
Same author

Exercise, Exerkines, and Sarcopenia.

Diabetes & metabolism journal·2026
Same author

Contrasting associations of body mass index and waist circumference with cancer incidence in the elderly: a nationwide population-based study.

Frontiers in oncology·2025
Same author

Association between sarcopenia and suicidal ideation in a nationwide population-based study.

Scientific reports·2025
Same author

The impact of parity on the risk of nonalcoholic fatty liver disease defined by hepatic steatosis index: A nationwide cohort study.

Scientific reports·2025
Same author

Impact of Adipose Tissue and Lipids on Skeletal Muscle in Sarcopenia.

Journal of cachexia, sarcopenia and muscle·2025

Related Experiment Video

Updated: Mar 12, 2026

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
03:52

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

1.4K

Sarcopenia and sarcopenic obesity.

Kyung Mook Choi1

  • 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.

The Korean Journal of Internal Medicine
|November 4, 2016
PubMed
Summary
This summary is machine-generated.

Sarcopenia, an age-related muscle loss, and sarcopenic obesity are growing public health concerns. Early identification and management are crucial for reducing associated health risks in older adults.

Keywords:
AgingMusclesObesitySarcopenia

More Related Videos

Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos
13:35

Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos

Published on: March 21, 2021

12.0K
Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles
04:00

Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles

Published on: July 26, 2024

1.5K

Related Experiment Videos

Last Updated: Mar 12, 2026

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
03:52

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

1.4K
Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos
13:35

Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos

Published on: March 21, 2021

12.0K
Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles
04:00

Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles

Published on: July 26, 2024

1.5K

Area of Science:

  • Gerontology
  • Muscle Physiology
  • Public Health

Background:

  • Sarcopenia, characterized by age-associated loss of muscle mass and strength, affects many older adults, increasing morbidity and mortality.
  • A universally accepted definition for sarcopenia is lacking, though recent research emphasizes muscle strength and physical performance alongside mass.
  • Sarcopenic obesity, a combination of sarcopenia and obesity, presents a critical public health challenge due to its rising prevalence and severe consequences.

Purpose of the Study:

  • To review current definitions and measurement techniques for sarcopenia.
  • To examine the health outcomes associated with sarcopenic obesity.
  • To highlight the impact of reduced muscle mass and strength on cardiometabolic disease mortality.

Main Methods:

  • Literature review of sarcopenia definitions and measurement techniques.
  • Analysis of studies on sarcopenic obesity prevalence and health outcomes.
  • Examination of research linking muscle mass/strength decline to cardiometabolic mortality.

Main Results:

  • Sarcopenia lacks a unified definition, with increasing focus on muscle strength and performance.
  • Sarcopenic obesity shares pathophysiological mechanisms with sarcopenia and obesity, potentially exacerbating both conditions.
  • Diminished muscle mass and strength are linked to increased mortality from cardiometabolic diseases.

Conclusions:

  • Sarcopenic obesity is a significant and growing public health risk in aging populations.
  • Further research is needed to improve the identification and management of sarcopenia and sarcopenic obesity in the elderly.
  • Addressing sarcopenia and sarcopenic obesity is vital for improving health outcomes and reducing mortality in older adults.